BioCardia SVP granted 39,521 RSUs as equity pay

GILLIS EDWARD M reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

GILLIS EDWARD M reported acquisition or exercise transactions in this Form 4 filing.

BioCardia, Inc. reported that Senior Vice President, Devices, Edward M. Gillis received a grant of 39,521 shares of common stock on June 29, 2026. These were issued as restricted stock units awarded as compensation in lieu of cash, at a reference value of $1.20 per share. All of the RSUs vested on June 29, 2026, and his directly held common stock position increased to 71,395 shares after the grant.

Insider Trade Summary

Grant/Award: 39,521 shares

Grant/Award 1 txn

Insider GILLIS EDWARD M

Role Senior Vice President, Devices

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	39,521	$1.20	$47K

Holdings After Transaction: Common Stock — 71,395 shares (Direct)

Footnotes (1)

1. F1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.

Key Figures

RSUs granted: 39,521 shares RSU value per share: $1.20 per share Total shares after grant: 71,395 shares +1 more

4 metrics

RSUs granted 39,521 shares Restricted stock units awarded as compensation in lieu of cash

RSU value per share $1.20 per share Reference price for the RSU grant

Total shares after grant 71,395 shares Directly held BioCardia common stock following the transaction

Vesting date June 29, 2026 100% of RSUs vested on this date

Key Terms

restricted stock units ("RSUs"), contingent right, compensation in lieu of cash

3 terms

restricted stock units ("RSUs") financial

"The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"each of which represents a contingent right to receive one share of the Issuer's common stock..."

compensation in lieu of cash financial

"common stock awarded as compensation in lieu of cash. 100% of the RSUs vested..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) report for Edward M. Gillis?

BioCardia reported that Senior Vice President, Devices, Edward M. Gillis received 39,521 restricted stock units of common stock as compensation in lieu of cash. All units vested on June 29, 2026, increasing his directly held common stock to 71,395 shares.

Was the BioCardia (BCDA) Form 4 transaction an open-market buy or sell?

The Form 4 transaction was not an open-market buy or sell. It reflects a grant of 39,521 restricted stock units awarded as compensation in lieu of cash, which vested in full on June 29, 2026, and increased the insider’s shareholdings.

How many BioCardia (BCDA) shares does Edward M. Gillis hold after this grant?

After the reported grant, Edward M. Gillis directly holds 71,395 shares of BioCardia common stock. This total includes the 39,521 restricted stock units that were awarded as compensation and fully vested on June 29, 2026, according to the Form 4 filing.

What are the key terms of the BioCardia (BCDA) restricted stock units granted?

The restricted stock units each represent a contingent right to receive one share of BioCardia common stock. A total of 39,521 RSUs were granted as compensation in lieu of cash, and 100% of these units vested on June 29, 2026, per the footnote disclosure.

At what price were the BioCardia (BCDA) RSUs valued in the Form 4?

The 39,521 restricted stock units granted to Edward M. Gillis were reported with a reference price of $1.20 per share. This price is used in the Form 4 to indicate the value of the equity-based compensation awarded instead of a cash payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 07:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS EDWARD M

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Devices

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		A		39,521(1)	A	$1.2(1)	71,395	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on June 29, 2026.

	/s/ David McClung, by power of attorney	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)